Notably, patients with ERBB2-amplified or overexpressing breast cancer can derive therapeutic benefits from ERBB2-targeted interventions, encompassing anti-ERBB2 antibodies (e.g., trastuzumab and epratuzumab) and small-molecule tyrosine kinase inhibitors (e.g., lapatinib and neratinib) [23]. This evidence concerns the gene ERBB2 and breast carcinoma.